Fax: (713) 794-4297
Outcome of adults with acute lymphocytic leukemia after second salvage therapy
Article first published online: 7 OCT 2008
Copyright © 2008 American Cancer Society
Volume 113, Issue 11, pages 3186–3191, 1 December 2008
How to Cite
O'Brien, S., Thomas, D., Ravandi, F., Faderl, S., Cortes, J., Borthakur, G., Pierce, S., Garcia-Manero, G. and Kantarjian, H. M. (2008), Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer, 113: 3186–3191. doi: 10.1002/cncr.23919
- Issue published online: 17 NOV 2008
- Article first published online: 7 OCT 2008
- Manuscript Accepted: 14 JUL 2008
- Manuscript Revised: 10 JUL 2008
- Manuscript Received: 4 JUN 2008
- acute lymphocytic leukemia;
- allogeneic stem cell transplantation;
- bone marrow blasts;
- prognostic factors;
- remission rate;
- second salvage therapy;
The outcome of adults with acute lymphocytic leukemia (ALL) who undergo second salvage therapy has been characterized poorly. This is important with regard to investigational approaches aimed at helping this subset of patients. The objectives of the current study were to predict outcomes and determine the prognostic factors associated with second salvage therapy in patients with ALL.
In this study, 288 patients were analyzed who received second salvage therapy for ALL at the authors' institution.
Overall, 53 patients (18%) achieved a complete response (CR). The median remission duration was 7 months and the median survival was 3 months. In multivariate analysis, prognostic factors that were associated independently with achieving CR were duration of first CR and platelet count. Patients with a first CR <36 months and platelet counts <50 × 109/L had an expected CR rate of 7%. In multivariate analysis, prognostic factors that were associated independently with survival were duration of first CR, percentage bone marrow blasts, platelet count, and albumin level. The expected 12-month survival rates for patients with 0 or 1, 2, 3, or 4 adverse factors were 33%, 14%, 8%, and 0%, respectively. A repeat multivariate analysis using landmark assessment at 6 weeks selected achievement of CR as adding significantly to the survival benefit (P = .0001; hazard ratio, 0.51). Only 22 patients (8%) were able to undergo allogeneic stem cell transplantation as second salvage therapy, and their 1-year survival rate was 18%.
The outcome of adults with ALL undergoing second salvage therapy is poor. Novel effective therapies against ALL are needed in this subset of patients. Cancer 2008. © 2008 American Cancer Society.